Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608750 | 0.87 | CYP11B1 (0.48) | CYP19A1SMN1; SMN2ALDH1A1NAMPTCYP11B1 | |
| SCHEMBL2121540 | 0.81 | ALDH1A1 (0.40) | CYP2C9CYP2C19CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL31074681 | 0.80 | ALDH1A1 (0.40) | CYP2C9CYP2C19CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL2608746 | 0.80 | ALDH1A1 (0.40) | CYP2C9CYP2C19CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL2608752 | 0.80 | ALDH1A1 (0.40) | CYP2C9CYP2C19CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL2122998 | 0.80 | ALDH1A1 (0.42) | CYP2C9CYP2C19CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL30725990 | 0.78 | DGAT1 (0.39) | CYP2C9CYP2C19CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL31074755 | 0.76 | CYP11B1 (0.40) | CYP2C9NPC1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL30726006 | 0.73 | HDAC1 (0.46) | CYP2C9CYP2C19CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL2608745 | 0.73 | ALDH1A1 (0.35) | CYP2C9CYP2C19CYP3A4CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735388-B2 | Heterocyclic compounds with affinity to muscarinic receptors | ABBVIE B.V. (NL) | 2014-05-27 | — | — | US | disclosed |
| US-8735388-B2 | Heterocyclic compounds with affinity to muscarinic receptors | ABBVIE B.V. (NL) | 2014-05-27 | — | — | US | disclosed |
| US-20140080861-A1 | HETEROCYCLIC COMPOUNDS IWTH AFFINITY TO MUSCARINIC RECEPTORS | ABBVIE B.V.A (NL) | 2014-03-20 | — | — | US | disclosed |
| US-20140080861-A1 | HETEROCYCLIC COMPOUNDS IWTH AFFINITY TO MUSCARINIC RECEPTORS | ABBVIE B.V.A (NL) | 2014-03-20 | — | — | US | disclosed |
| US-8586606-B2 | Heterocyclic compounds with affinity to muscarinic receptors | ABBVIE B.V. (NL) | 2013-11-19 | — | — | US | disclosed |
| US-20120095039-A1 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. | 2012-04-19 | — | — | US | disclosed |
| US-20120095039-A1 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. | 2012-04-19 | — | — | US | disclosed |
| US-8084473-B2 | Heterocyclic compounds with affinity to muscarinic receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-12-27 | — | — | US | disclosed |
| US-8084473-B2 | Heterocyclic compounds with affinity to muscarinic receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-12-27 | — | — | US | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| WO-2008129054-A2 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095039-A1 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | CHRM3, CHRM5, CHRM2 | CYP2C9 700/4885CYP2C19 482/4885CYP3A4 369/4885 |
| US-20140080861-A1 | HETEROCYCLIC COMPOUNDS IWTH AFFINITY TO MUSCARINIC RECEPTORS | CHRM3, CHRM4, CHRM5 | CYP2C9 661/4885CYP2C19 482/4885CYP3A4 392/4885 |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | CHRM3, CHRM2, CHRM1 | CYP2C9 836/4885CYP2C19 1027/4885CYP3A4 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.